



MAYNE PHARMA APPOINTS NEW BOARD MEMBER

26 August 2014, Melbourne Australia: Mayne Pharma Group Limited (ASX: MYX) is pleased to announce that Professor Bruce G Robinson has accepted an invitation to join the Board of Mayne Pharma Group Limited, effective immediately.

Professor Robinson is Dean of Sydney Medical School at the University of Sydney, a position he has held since 2007. As Dean, he leads one of the largest medical schools in Australia and the most research-intensive faculty within the University of Sydney.

Professor Robinson is an Endocrinologist and practices at Sydney's Royal North Shore Hospital. Professor Robinson has also been the head of the Cancer Genetics Unit at the Kolling Institute of Medical Research, Royal North Shore Hospital since 1989.

Professor Robinson has supervised 37 PhD students and has more than 250 research publications.

Since 2001, he has been Chairman of Hoc Mai Foundation, a major program to improve health outcomes through education and exchange in Vietnam. He is a Board Member of the Woolcock Institute, the ANZAC Research Institute and the Centenary Institute for Cancer Research. He is also a Board Member of the Royal Flying Doctor Service (South-Eastern Division) and is Chair of RFDS Medical Advisory Committee.

Mayne Pharma Chairman Mr Roger Corbett, AO said, "Bruce has an impressive CV and brings a wealth of knowledge to Mayne Pharma. His extensive experience and research background will be highly complementary to the skill sets of the other Board members. Mayne Pharma is fortunate to have been able to secure Bruce's services."

Professor Robinson's appointment will be voted on by Shareholders at the Company's AGM in November.

For further information contact:

Scott Richards +61 8 8209 2410

Lisa Pendlebury +61 419 548 434, lisa.pendlebury@maynepharma.com

About Mayne Pharma

Mayne Pharma is an ASX-listed specialty pharmaceutical company that develops and manufactures branded and generic products, which it distributes globally; either directly or through distribution partners and also provides contract development and manufacturing services.

Mayne Pharma has a 30-year track record of innovation and success in developing new oral drug delivery systems and these technologies have been successfully commercialised in numerous products that have been marketed around the world.

Mayne Pharma has two drug development and manufacturing facilities based in Salisbury, Australia and Greenville, USA with expertise in formulation complex oral dose forms including highly potent compounds, controlled substances, modified release products and inherently unstable compounds.